NK
NKTR
NEKTAR THERAPEUTICS
$69.49
+2.83%
$2.3B
No data for this timeframe.
Vol
Market Cap$2.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders9 funds
Inst. Value$107.3M
Inst. Activity2 buys / 3 sells
Insider Activity0B / 2S
Insider Net $-$44.0K
Reddit Sentiment67° Warm
SEC Reports7
Recent Activity
May 8, 2026
SEC
Nektar Therapeutics entered into an at-the-market equity distribution agreement to sell up to $150 million of common sto
8-K — Impact 5/10
May 7, 2026
SEC
Nektar Therapeutics reported Q1 2026 revenue of $10.9M (+3.8% YoY) and a net loss of $44.9M ($1.82 per share), improving
8-K — Impact 4/10
Apr 24, 2026
SEC
Nektar Therapeutics filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, which includes routine mat
DEFA14A — Impact 3/10
Feb 18, 2026
Insider
ROBIN HOWARD W sold 423 shares
President & CEO @ $73.00 ($30.9K)
Feb 18, 2026
Insider
Zalevsky Jonathan sold 180 shares
Chief R&D Officer @ $73.00 ($13.1K)
Inst.
MORGAN STANLEY — TRIM
566,421 shares ($23.9M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
172,881 shares ($7.3M)
May 7, 2026
earnings_calendar
NKTR Q1 2026 Earnings After Market Close — 2026-05-07
Price Targets
$153.25
+120.5% upside
Strong Buy
Current $69.49
Low $80.00
Median $150.50
High $192.00
8 analysts
$80.00
$192.00
Analyst Ratings
7Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 21, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.04 | $-2.74 — $-1.72 | 27% YoY | 4 |
| Next Q | $-0.52 ▲ +55.5% | $-3.15 — $5.30 | 72% YoY | 4 |
| Current FY | $-9.54 ▲ +4.7% | $-11.02 — $-7.62 | -10% YoY | 4 |
| Next FY | $-12.56 ▼ -11.8% | $-14.04 — $-10.18 | -32% YoY | 4 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $43.4M | ADD |
| MORGAN STANLEY | $23.9M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $20.0M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $7.3M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 18, 2026 | ROBIN HOWARD | SELL | $30.9K |
| Feb 18, 2026 | Zalevsky Jonathan | SELL | $13.1K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
9 institutional holders with $107.3M total value (2,537,197 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,027,089 | $43.4M | 40.5% | ADD +30.0% |
| 2 | MORGAN STANLEY | 566,421 | $23.9M | 22.3% | TRIM -39.0% |
| 3 | TWO SIGMA INVESTMENTS, LP | 473,014 | $20.0M | 18.6% | DOUBLED +446.9% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 172,881 | $7.3M | 6.8% | TRIM -37.9% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 120,380 | $5.1M | 4.7% | ADD +73.9% |
| 6 | FMR LLC | 101,129 | $4.3M | 4.0% | DOUBLED +153.0% |
| 7 | NORGES BANK | 50,000 | $2.1M | 2.0% | NEW |
| 8 | BANK OF AMERICA CORP /DE/ | 26,092 | $1.1M | 1.0% | TRIM -45.6% |
| 9 | WELLS FARGO & COMPANY/MN | 191 | $8.1K | 0.0% | TRIM -52.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 929,151 | 566,421 | -39.0% | $23.9M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 278,541 | 172,881 | -37.9% | $7.3M | 2025-Q4 |
| FMR LLC | DOUBLED | 39,967 | 101,129 | +153.0% | $4.3M | 2025-Q4 |
| NORGES BANK | NEW | — | 50,000 | — | $2.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 47,959 | 26,092 | -45.6% | $1.1M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 729,492 | 948,647 | +30.0% | $54.0M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 72,139 | 929,151 | +1188.0% | $52.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 79,395 | 434,237 | +446.9% | $24.7M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 65,929 | 114,664 | +73.9% | $6.5M | 2025-Q3 |
| UBS Group AG | TRIM | 201,371 | 90,822 | -54.9% | $5.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 67,561 | 47,959 | -29.0% | $2.7M | 2025-Q3 |
| FMR LLC | DOUBLED | 15,276 | 39,967 | +161.6% | $2.3M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 517 | 248 | -52.0% | $14.1K | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 729,492 | — | $18.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 247,060 | — | $6.4M | 2025-Q2 |
| UBS Group AG | NEW | — | 201,371 | — | $5.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 79,395 | — | $2.1M | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 72,139 | — | $1.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 67,561 | — | $1.7M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 65,929 | — | $1.7M | 2025-Q2 |
| FMR LLC | NEW | — | 15,276 | — | $394.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 517 | — | $13.4K | 2025-Q2 |
| FMR LLC | EXIT | 233,964 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 12,309,688 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | EXIT | 584,117 | 0 | -100.0% | $0.00 | 2025-Q2 |
2 unique insiders with 2 transactions. Net insider value: -$44.0K ($0.00 bought, $44.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | ROBIN HOWARD W | President & CEO | SELL | 423 | $73.00 | $30.9K |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | SELL | 180 | $73.00 | $13.1K |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 4.7/10.
BEARISH
8-K
5/10
Nektar Therapeutics entered into an at-the-market equity distribution agreement to sell up to $150 m
May 8, 2026
NEUTRAL
8-K
4/10
Nektar Therapeutics reported Q1 2026 revenue of $10.9M (+3.8% YoY) and a net loss of $44.9M ($1.82 p
May 7, 2026
NEUTRAL
DEFA14A
3/10
Nektar Therapeutics filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, which
Apr 24, 2026
NEUTRAL
8-K
5/10
Nektar Therapeutics raised approximately $325 million through an upsized public offering of 3,532,60
Apr 23, 2026
BULLISH
424B5
7/10
Nektar Therapeutics is raising approximately $305.1 million through a public offering of 3.53 millio
Apr 23, 2026
MIXED
424B5
6/10
Nektar Therapeutics is conducting a $250 million follow-on offering of common stock and pre-funded w
Apr 20, 2026
NEUTRAL
8-K
3/10
Nektar Therapeutics disclosed it had approximately $741.7 million in cash and marketable securities
Apr 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 7 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$153.25 mean target
+120.5% upside
Strong Buy (1.30)
$80.00 Low
$192.00 High
| Metric | Value |
|---|---|
| Current Price | $69.49 |
| Target Low | $80.00 |
| Target Mean | $153.25 |
| Target Median | $150.50 |
| Target High | $192.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.04 | $-2.74 | $-1.72 | 26.7% | +0.1% | 2↑ 0↓ | $0.0B | -7.1% | 4 |
| Next Q 2026-09-30 |
$-0.52 | $-3.15 | $5.30 | 72.4% | +55.5% | — | $0.0B | -13.7% | 4 |
| Current FY 2026-12-31 |
$-9.54 | $-11.02 | $-7.62 | -10.2% | +4.7% | 1↑ 1↓ | $0.0B | -25.4% | 4 |
| Next FY 2027-12-31 |
$-12.56 | $-14.04 | $-10.18 | -31.6% | -11.8% | 0↑ 3↓ | $0.0B | -10.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.038 | |
| 7d ago | $-1.647 | -0.390 |
| 30d ago | $-2.040 | +0.002 |
| 60d ago | $-2.185 | +0.147 |
| 90d ago | $-2.920 | +0.882 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Wedbush | INITIATE | — | Neutral |
| Mar 17, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 16, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | B. Riley Securities | REITERATE | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 16, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Nov 26, 2025 | Citigroup | INITIATE | — | Buy |
| Nov 26, 2025 | Jefferies | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
5 mentions
3 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 16, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CUE is the better NKTR now
▲ 1
💬 1
⚡ 0.5
Lat post on CUE before it's not a penny stock
▲ 1
💬 1
⚡ 0.5
CUE is now the Better NKTR
▲ 1
💬 1
⚡ 0.5
May 7, 2026
earnings_calendar
NKTR Q1 2026 Earnings After Market Close — 2026-05-07
Apr 27, 2026
short_volume
Short Volume: NKTR — 63.9% short (0.4M / 0.7M)
Short: 445,176 | Exempt: 1,024 | TRF Vol: 696,992 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Mar 20, 2026
short_interest
FTD: NKTR — 17,825 shares ($1.3M) failed to deliver
Settlement: 20260320, Price: $74.84, FTD Value: $1,334,023, NEKTAR THERAPEUTICS
Mar 12, 2026
earnings_calendar
NKTR Q4 2025 Earnings After Market Close — 2026-03-12
Mar 4, 2026
earnings_calendar
NKTR Q4 2025 Earnings After Market Close — 2026-03-04
Feb 3, 2026
short_interest
FTD: NKTR — 29,789 shares ($1.1M) failed to deliver
Settlement: 20260203, Price: $38.12, FTD Value: $1,135,556.68, NEKTAR THERAPEUTICS